Sfoglia per Soggetto "rhinopharyngitis"

Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: A combined task force of the IRLSSG, EURLSSG, and the RLS-foundation

Garcia-Borreguero D., Silber M.H., Winkelman J.W., Högl B., Bainbridge J., Buchfuhrer M., Hadjigeorgiou G., Inoue Y., Manconi M., Oertel W., Ondo W., Winkelmann J., Allen R.P. (2016)

A Task Force was established by the International Restless Legs Syndrome Study Group (IRLSSG) in conjunction with the European Restless Legs Syndrome Study Group (EURLSSG) and the RLS Foundation (RLS-F) to develop ...

New therapeutic strategies for the treatment of male lower urinary tract symptoms

Dimitropoulos K., Gravas S. (2016)

Male lower urinary tract symptoms (LUTS) are prevalent in the general population, especially in those of advanced age, and are characterized by notable diversity in etiology and presentation, and have been proven to cause ...

Outcomes of combination therapy with daily tadalafil 5 mg plus tamsulosin 0.4 mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome

Sebastianelli A., Morselli S., Spatafora P., Liaci A., Gemma L., Zaccaro C., Vignozzi L., Maggi M., McVary K.T., Kaplan S.A., Chapple C., Gravas S., Serni S., Gacci M. (2022)

BACKGROUND: The aim of this study was to assess the impact of tadalafil 5 mg/die plus tamsulosin 0.4 mg/die combination therapy on lower urinary tract symptoms (LUTS) and erectile dysfunction (ED), according to presence ...

Safety and tolerability of β 3-adrenoceptor agonists in the treatment of overactive bladder syndrome - Insight from transcriptosome and experimental studies

Michel M.C., Gravas S. (2016)

Introduction: We have reviewed the safety and tolerability of β3-adrenoceptor agonists, specifically mirabegron and solabegron, a newly emerging drug class for the treatment of the overactive bladder syndrome. We discuss ...

Tadalafil 5 mg alone or in combination with tamsulosin 0.4 mg for the management of men with lower urinary tract symptoms and erectile dysfunction: Results of a prospective observational trial

Sebastianelli A., Spatafora P., Frizzi J., Saleh O., Sessa M., De Nunzio C., Tubaro A., Vignozzi L., Maggi M., Serni S., McVary K.T., Kaplan S.A., Gravas S., Chapple C., Gacci M. (2019)

Tadalafil 5 mg represents the standard for men with Erectile dysfunction (ED) and lower urinary tract symptoms (LUTS)/benign prostatic enlargement (BPE). We carried out an observational trial aiming to assess the efficacy ...

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED

Sebastianelli A., Spatafora P., Morselli S., Vignozzi L., Serni S., McVary K.T., Kaplan S., Gravas S., Chapple C., Gacci M. (2020)

Purpose of Review: Aim of our systematic review is to evaluate and summarize the efficacy and safety of tadalafil alone or in combination with tamsulosin for the management of lower urinary tract symptoms (LUTS)/benign ...

Upadacitinib tartrate in rheumatoid arthritis

Stamatis P., Bogdanos D.P., Sakkas L.I. (2020)

does not achieve low disease activity or remission despite the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or biological DMARDs (bDMARDs). The Janus kinase (JAK) inhibitors are the ...